Purpose: The use of a combined physician-and pharmacist-directed phenytoin loading dose program in an emergency department (ED) was evaluated.
Methods: This single-center, observational, preimplementation-postimplementation study evaluated adult patients who received a phenytoin loading dose in the ED. The primary outcome compared the proportion of optimal phenytoin loading doses in the preimplementation and postimplementation groups. The postimplementation group was further stratified into pharmacist- and prescriber-dosing groups. Other outcomes evaluated included the numbers of appropriate serum phenytoin concentrations measured, adverse drug reactions (ADRs), and recurrence of seizures within 24 hours of loading dose administration in the preimplementation and postimplementation groups.
Results: There was no difference in the proportion of optimal phenytoin loading doses between the preimplementation and postimplementation groups (50% versus 62%, respectively; p=0.19). When stratified by individual groups, the rate of optimal phenytoin loading doses increased by 64% in the postimplementation pharmacist group (50% versus 82%, p=0.007), while the rate in the prescriber-dosing group remained relatively unchanged (50% versus 49%, p=0.91). The number of appropriate serum phenytoin concentrations significantly improved in the postimplementation versus preimplementation group (65% versus 40%, p=0.025). Rates of ADRs and recurrence of seizures did not differ across the study groups.
Conclusion: No change in the percentage of optimal phenytoin loading doses in the ED was observed after implementation of a combined pharmacist- and physician- dosing program. When stratified into pharmacist or prescriber dosing, the pharmacist-led dosing program significantly improved the proportion of patients who received optimal phenytoin loading doses.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2146/ajhp140039 | DOI Listing |
Front Pharmacol
November 2024
Departamento de Ciencias del Ambiente, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile.
Background: A growing body of research is dedicated to developing new therapeutic agents for wound healing with fewer adverse effects. One of the proceedings being taken today in wound healing research is to identify promising biological materials that not only heal wounds but also vanish scarring. The effectiveness of nanofibers like polyvinyl alcohol (PVA), in improving wound healing can be related to their unique properties.
View Article and Find Full Text PDFInt J Pharm
December 2024
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral St, Glasgow G4 0RE, UK.
Wound healing is a complex biological process crucial for tissue repair, especially in chronic wounds where healing is impaired. Liposomes have emerged as promising vehicles for delivering therapeutics to facilitate wound repair. Liposomes have been explored as effective carriers for therapeutic agents.
View Article and Find Full Text PDFInt J Biol Macromol
December 2024
Department of Chemical and Biomolecular Engineering, Chonnam National University, Yeosu 59626, Republic of Korea; Emerging Pathogens Institute, Department of Animal Sciences, University of Florida, Gainesville, FL 32611, United States. Electronic address:
This study aimed to synthesize phenytoin (PHT)-loaded water chestnut starch-based biomaterials and evaluate their drug release kinetics for use in transdermal drug delivery systems for antiepileptic therapy. Hierarchical microparticles (HMPs) extracted from human hair were also used to improve the PHT release efficiency. The physicochemical characteristics of PHT, HMPs, and the prepared biomaterials were evaluated by physical properties, antimicrobial activities, FE-SEM, FT-IR, XRD, H NMR, and C CPMAS solid-state NMR.
View Article and Find Full Text PDFCase Rep Neurol Med
October 2024
Faculty of Medicine, Universiti Teknologi MARA, JLN Hospital, Sungai Buloh 47000, Selangor, Malaysia.
An 18-year-old male presented with new-onset focal to bilateral tonic-clonic seizures 5 days after receiving the first dose of COVID-19 vaccine. 3 days later, an identical seizure occurred lasting 1 min, leading to an acute presentation to the hospital. In hospital, the patient was loaded with intravenous phenytoin and started on levetiracetam with no further seizure recurrence.
View Article and Find Full Text PDFInt J Pharm
December 2024
Department of Pharmacy, University of Oslo. Sem Sælands vei 3, 0371 Oslo, Norway.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!